Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Herpes zoster vaccine, and preparation method and application thereof

A technology of herpes zoster and herpes zoster virus, which is applied in the field of vaccines, can solve problems such as high safety risks of vaccines, and achieve the effects of enhancing cellular and humoral immune responses, improving immune effects, and enhancing Th1 responses

Inactive Publication Date: 2018-12-14
ANHUI ZHIFEI LONGCOM BIOPHARM CO LTD +2
View PDF11 Cites 17 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] Aiming at the problem that the existing herpes zoster vaccine has a higher safety risk, the present invention provides a herpes zoster vaccine, the adjuvant of which is Poly(I:C)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Herpes zoster vaccine, and preparation method and application thereof
  • Herpes zoster vaccine, and preparation method and application thereof
  • Herpes zoster vaccine, and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] Embodiment 1 The preparation of the vaccine containing recombinant varicella zoster virus (VZV) gE protein

[0041] Experimental materials and sources:

[0042] CHO cell line, purchased from Thermo company;

[0043] CD CHO medium was purchased from Thermo Fisher.

[0044] Preparation:

[0045] 1. The recombinant CHO cell line stably expressing the VZV gE protein adopts a well-known method, according to the amino acid sequence of the VZV gE protein found on the NCBI website, synthesizes the gene sequence, and transfects it into CHO cells according to the method described in the "Molecular Cloning Experiment Guide". Monoclonal cells were selected by the limiting dilution method, and after multiple rounds of screening, they were expanded and cultured in cell shake flasks and then frozen. After collecting the supernatant of the subcloned cells, samples were taken for Western Blot detection. According to the gray scale of the bands, the monoclonal cells with higher expres...

Embodiment 2

[0053] Embodiment 2 Preparation of vaccine containing recombinant varicella-zoster virus (VZV) gE protein

[0054] Experimental materials and sources:

[0055] CHO cell line, purchased from Thermo company;

[0056] CD CHO medium was purchased from Thermo Fisher.

[0057] Preparation:

[0058] 1. The recombinant CHO cell line stably expressing the VZV gE protein adopts a well-known method, according to the amino acid sequence of the VZV gE protein found on the NCBI website, synthesizes the gene sequence, and transfects it into CHO cells according to the method described in the "Molecular Cloning Experiment Guide". Monoclonal cells were selected by the limiting dilution method, and after multiple rounds of screening, they were expanded and cultured in cell shake flasks and then frozen. After collecting the supernatant of the subcloned cells, samples were taken for Western Blot detection. According to the gray scale of the bands, the monoclonal cells with higher expression lev...

Embodiment 3

[0066] Embodiment 3 Preparation of vaccine containing recombinant varicella-zoster virus (VZV) gE protein

[0067] Experimental materials and sources:

[0068] CHO cell line, purchased from Thermo company;

[0069] CD CHO medium was purchased from Thermo Fisher.

[0070] Preparation:

[0071] 1. The recombinant CHO cell line stably expressing the VZV gE protein adopts a well-known method, according to the amino acid sequence of the VZV gE protein found on the NCBI website, synthesizes the gene sequence, and transfects it into CHO cells according to the method described in the "Molecular Cloning Experiment Guide". Monoclonal cells were selected by the limiting dilution method, and after multiple rounds of screening, they were expanded and cultured in cell shake flasks and then frozen. After collecting the supernatant of the subcloned cells, samples were taken for Western Blot detection. According to the gray scale of the bands, the monoclonal cells with higher expression lev...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a herpes zoster vaccine, and a preparation method and an application thereof, and belongs to the field of vaccines. The herpes zoster vaccine is provided against the problem ofhigh safety risk of existing herpes zoster vaccines, and an adjuvant used by the herpes zoster vaccine is Poly (I:C). The Poly(I:C) is called polyinosinic-polycytidylic acid for short, and is double-stranded RNA, and the safety of the Poly(I:C) is confirmed during large-scale clinical application. The Poly(I:C) is a high-efficiency interferon inducer, can produce an immune reaction like viral infection in vivo, and can induce CD4<+> and CD8<+> T cells and enhance cellular and humoral immune responses.

Description

technical field [0001] The invention belongs to the field of vaccines, and in particular relates to a herpes zoster vaccine and its preparation method and application. Background technique [0002] Herpes zoster (HZ) is an acute infectious skin disease caused by recurrent infection of varicella-zoster virus (VZV) latent in the sensory ganglion, clinically manifested as lesions on one side of the body Herpes, typically confined to a dermatome, is often accompanied by radicular pain. Patients experience significant pain and discomfort, which may last for weeks, months, or years in severe cases, reducing the quality of life. A common serious complication is post-herpetic neuralgia (Post-Herpetic Neuralgia, PHN). Data show that more than 90% of adults are at risk of herpes zoster, and the risk of herpes zoster infection in people over the age of 50 is significantly higher, which may be associated with previous infection with wild-type varicella virus (VZV) virus, and is prone ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/39A61K39/245A61P31/22A61P25/00
CPCA61K39/12A61K39/39A61P25/00A61P31/22A61K2039/55511A61K2039/5252A61K2039/54C12N2710/16734A61K2039/55561A61K2039/575
Inventor 谭小东杨世龙方超庄宗兰刘琳邵志远金香玉彭杰
Owner ANHUI ZHIFEI LONGCOM BIOPHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com